Abstract
ATP binding cassette (ABC)-containing drug efflux transporters play important roles in regulating intracellular drug concentrations that determine cell sensitivity to chemotherapeutic agents. Of particular relevance to cancer chemotherapy are the transporters P-glycoprotein (Pgp) encoded by multidrug resistance 1 gene, multidrug resistance protein (MRP), and breast cancer resistance protein (BCRP). More than 80% of currently used antitumor agents can be transported by these three transporters, and overexpression of these transporters renders multidrug resistance to a broad spectrum of antitumor agents. Elevated expression of these transporters is frequently found in breast cancers and correlations with elevated expression of Pgp or MRP1 to chemotherapeutic outcomes have been observed in some cases, suggesting that these transporters may contribute to chemoresistance in breast cancers. However, attempts to modulate the activities of these transporters using reversal agents have met with limited success. Future studies should focus on better understanding of the upregulation mechanisms of ABC transporter genes in breast cancers, and of the pharmacologic mechanisms of transporter-reversal agent interactions. These studies may lead to novel strategies for improving chemotherapeutic efficacies through targeted interventions of these ABC transporters.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6:229–239.
Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA cancer J Clin 2004; 54:8–29.
Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Cancer 2004; 100:44–52.
Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339:974–984.
Piccart M. The roles of taxenes in the adjuvant treatment of early breast cancers. Breast Cancer Res Treat 2003; 79:S25–S34.
Nabholtz JMA. Docetaxel-an thracycline combinations in metastatic brease cancers. Breast Cancer Res Treat 2003; 79:S3–S9.
Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13:23886–2894.
Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Onco 1996; 14:1858–1867.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biophys Acta Biochim 1975; 445:152–162.
Cole SP, Bhardway JH, Gerlach JE et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258:1650–1654.
Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 5:15665–15670.
Deng L, Tatebe S, Lin-Lee YC et al. MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer Treat Res 2002; 112:49–66.
Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 2003; 55:3–29.
Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71:537–592.
Chang G, Roth CB. Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001; 293:1793–1800.
Higgins CF, Linton KJ. The ATP switch model for ABC transporter. Nature Struct Mol Biol 2004; 11:918–926.
Schinkel AH, Smit JJM, Van Tellingen O et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77:491–502.
Schinkel AH, Mayer U, Wagenaar E et al. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94:4028–4033.
Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003; 22:7496–7511.
Kuo MT, Liu Z, Wei Y et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 2002; 21:1945–1954.
Zhan M, Yu D, Lin J et al. Transcriptional repression of protein kinase Cα via Sp1 by wild-type p53 is involved in inhibition of MDR1 P-glycoprotein phosphorylation. J Biol Chem 2005; 280:4825–4833.
Bakos E, Evers R, Szakacs G et al. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 1998; 273:32167–32175.
Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22:7537–7552.
Heimeur A, Conseil G, Deeley RG et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr Drug Metab 2004; 5:21–53.
Wijnholds J, Evers R, van Leusden MR et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Med 1997; 3:1275–1279.
Keppler D, Kartenbeck J. The canalicular conjugate export pump encoded by the cmrp/cmoat gene. Prog Liver Dis 1996; 14:55–67.
Zelcer N, Saeki T, Reid G et al. Characterization of drug transport by the human mulltidrug resistance protein 3 (ABCC3). J Biol Chem 2001; 276:46400–46407.
Schuetz JD, Connelly MC, Sun D et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Naure Med 1999; 5:1048–1051.
Yamane Y, Furuichi M, Song R et al. Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem 1998; 273:31075–31085.
Kuo MT, Bao JJ, Curley SA et al. Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res 1996; 56:3642–3644.
Zipper LM, Mulcahy RT. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 2002; 277:36544–36552.
Lin-Lee YC, Tatebe S, Savaraj N et al. Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochem Pharmacol 2001; 61:555–563.
Allen JD, Schinkel AH. Multidrug resistance and pharmacological protein mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Therap 2002; 1:427–434.
Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22:7340–7358.
Bates SE, Robey R, Miyake K et al. The roles of half-transporters in multidrug resistance. J Bioenergetics and Biomem 2001; 33:503–517.
Jonker JW, Buitelaar M, Wagenaar E et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99:15649–15654.
Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in brease cancer. Endocrine-related Cancer 2003; 10:43–73.
Beck WT, Grogan TM, Willman CL et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: Consensus recommendations. Cancer Res 1996; 56:3010–3020.
Verrelle P, Meissonnier F, Fonck Y et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Nat Cancer Inst 1991; 83:111–116.
Chevillard S, Pouillart P, Beldjord C et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996; 77:292–300.
Rudas M, Filipits M, Taucher S et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 2003; 81:149–157.
Filipits M, Malayeri R, Suchomel RW et al. Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res 1999; 19:5043–5049.
Ferrero JM, Etienne MC, Formento JL et al. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. Br J Cancer 2000; 82:171–177.
Faneyte IF, Kristel PM, van de Vijver MJ. Multidurg resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 2004; 24:2931–2939.
Kanzaki A, Toi M, Nakayama K et al. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 2001; 92:452–458.
Van den Heuvel-Eibrink MM, Wiemer EA, Prins A et al. Leukemia. 2002; 16:833–839.
Sargent JM, Williamson CJ, Maliepaard M et al. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Brit J Haematol 2001; 115:257–262.
Faneyte IF, Kristel PM, Maliepaard M et al. Expression of the breast cancer resistance protein in breast cancer. Clinic Cancer Res 2002; 8:1068–1074.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Kuo, M.T. (2007). Roles of Multidrug Resistance Genes in Breast Cancer Chemoresistance. In: Yu, D., Hung, MC. (eds) Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology, vol 608. Springer, New York, NY. https://doi.org/10.1007/978-0-387-74039-3_2
Download citation
DOI: https://doi.org/10.1007/978-0-387-74039-3_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-74037-9
Online ISBN: 978-0-387-74039-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)